Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 351

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Trial of Cinpanemab in Early Parkinson’s Disease

Open access
Lang, Anthony E., Siderowf, Andrew D., Macklin, Eric A., Poewe, Werner, Brooks, David J., Fernandez, Hubert H., Rascol, Olivier, Giladi, Nir, Stocchi, Fabrizio, Tanner, Caroline M., Postuma, Ronald B., Simon, David K., Tolosa, Eduardo, Mollenhauer, Brit, Cedarbaum, Jesse M., Fraser, Kyle, Xiao, James, Evans, Karleyton C., Graham, Danielle L., Sapir, Inbal, Inra, Jennifer, Hutchison, R. Matthew, Yang, Minhua, Fox, Tara, Budd Haeberlein, Samantha, Dam, Tien·2022·New England Journal of Medicine

Abstract

BACKGROUND: Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease. METHODS: In a 52-week, multicenter, double-blind, phase 2 trial, we randomly assigned, in a 2:1:2:2 ratio, participants with early Parkinson's disease to receive intravenous infusions of placebo (control) or cinpanemab at a dose of 250 mg, 1250 mg, or 3500 mg every 4 weeks, followed by an active-treatment dose-blinded extension period for up to 112 weeks. The primary end points were the changes from baseline in the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score (range, 0 to 236, with higher scores indicating worse performance) at weeks 52 and 72. Secondary end points included MDS-UPDRS subscale scores and striatal binding as assessed on dopamine transporter single-photon-emission computed tomography (DaT-SPECT). RESULTS: Of the 357 enrolled participants, 100 were assigned to the control group, 55 to the 250-mg cinpanemab group, 102 to the 1250-mg group, and 100 to the 3500-mg group. The trial was stopped after the week 72 interim analysis owing to lack of efficacy. The change to week 52 in the MDS-UPDRS score was 10.8 points in the control group, 10.5 points in the 250-mg group, 11.3 points in the 1250-mg group, and 10.9 points in the 3500-mg group (adjusted mean difference vs. control, -0.3 points [95% confidence interval {CI}, -4.9 to 4.3], P = 0.90; 0.5 points [95% CI, -3.3 to 4.3], P = 0.80; and 0.1 point [95% CI, -3.8 to 4.0], P = 0.97, respectively). The adjusted mean difference at 72 weeks between participants who received cinpanemab through 72 weeks and the pooled group of those who started cinpanemab at 52 weeks was -0.9 points (95% CI, -5.6 to 3.8) for the 250-mg dose, 0.6 points (95% CI, -3.3 to 4.4) for the 1250-mg dose, and -0.8 points (95% CI, -4.6 to 3.0) for the 3500-mg dose. Results for secondary end points were similar to those for the primary end points. DaT-SPECT imaging at week 52 showed no differences between the control group and any cinpanemab group. The most common adverse events with cinpanemab were headache, nasopharyngitis, and falls. CONCLUSIONS: In participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period. (Funded by Biogen; SPARK ClinicalTrials.gov number, NCT03318523.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2203395

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 351

Metadata

Authors
Lang, A. E., Siderowf, A. D., Macklin, E. A., Poewe, W., Brooks, D. J., Fernandez, H. H., Rascol, O., Giladi, N., Stocchi, F., Tanner, C. M., Postuma, R. B., Simon, D. K., Tolosa, E., Mollenhauer, B., Cedarbaum, J. M., Fraser, K., Xiao, J., Evans, K. C., Graham, D. L., Sapir, I., Inra, J., Hutchison, R. M., Yang, M., Fox, T., Budd Haeberlein, S., & Dam, T.
Venue
New England Journal of Medicine
Published
2022-08-04
Volume
387
Issue
5
Pages
408-420
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4289667121
Cited by
351
References
19
FWCI
32.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial of Cinpanemab in Early Parkinson’s Disease. https://app.cochat.ai/papers/10.1056/nejmoa2203395
The paper
Lang, A. E., Siderowf, A. D., Macklin, E. A., Poewe, W., Brooks, D. J., Fernandez, H. H., Rascol, O., Giladi, N., Stocchi, F., Tanner, C. M., Postuma, R. B., Simon, D. K., Tolosa, E., Mollenhauer, B., Cedarbaum, J. M., Fraser, K., Xiao, J., Evans, K. C., Graham, D. L., . . . Dam, T. (2022). Trial of Cinpanemab in Early Parkinson’s Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2203395

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.